Cidara Therapeutics Stock News

Compass Therapeutics (OTC:CMPX) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation. Insider & Institutional Ownership 47.4% of Cidara Therapeutics shares are held by institutional investors. 8.0% […]

Cidara Therapeutics (NASDAQ:CDTX) had its price target boosted by Wedbush from $5.00 to $6.00 in a research report sent to investors on Thursday, Analyst Ratings Network reports. The brokerage currently has an outperform rating on the biotechnology companys stock. A number of other research firms also recently issued reports on CDTX. HC Wainwright assumed coverage [] The post Cidara Therapeutics (NASDAQ:CDTX) Price Target Increased to $6.00 by Analysts at Wedbush appeared first on ETF Daily News .

During the last session, Cidara Therapeutics Inc. (NASDAQ:CDTX)’s traded shares were 2.04 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $1.39, reflecting an intraday gain of 13.93% or $0.17. The 52-week high for the CDTX share is $3.15, that puts it down … Is Cidara Therapeutics Inc. (NASDAQ: CDTX) Still A Buy After sinking -14.72% Last Week? Read More »

Cidara Therapeutics Inc (NASDAQ: CDTX) and Mundipharma posted topline data from the ReSTORE Phase 3 trial of rezafungin for candidemia and invasive candidiasis. Rezafungin met the FDA primary endp

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX ) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) submission of all-cause mortality at Day 30, and also met the primary endpoint for the European Medicines Agency (EMA) Marketing Authorization Application (MAA) submission of global cure at Day 14. Both results demonstrated statistical non-inferiority of rezafungin dosed once-weekly, versus caspofungin dosed once-daily, the current standard of care.

Millennium Management LLC grew its stake in Cidara Therapeutics, Inc. (NASDAQ:CDTX) by 810.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 580,793 shares of the biotechnology companys stock after purchasing an additional 517,023 shares during the period. Millennium Management LLC owned approximately []

Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.

Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.

Twist Bioscience (NASDAQ:TWST) and Cidara Therapeutics (NASDAQ:CDTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Profitability This table compares Twist Bioscience and Cidara Therapeutics net margins, return on equity and return []

Penny stocks to watch even with Biotech ETFs heading lower today. The post 3 Biotech Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Infor

Cidara Therapeutics Inc. (NASDAQ:CDTX) has a beta value of 1.10 and has seen 1.18 million shares traded in the last trading session. The company, currently valued at $100.02M, closed the last trade at $1.49 per share which meant it gained $0.06 on the day or 4.20% during that session. The CDTX stock price is -111.41% Weak Fundamental Momentum Sinks Cidara Therapeutics Inc. Read More »

Cidara Therapeutics (NASDAQ:CDTX) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a []

In the last trading session, 3.5 million shares of the Cidara Therapeutics Inc. (NASDAQ:CDTX) were traded, and its beta was 1.10. Most recently the company’s share price was $1.53, and it changed around $0.13 or 9.29% from the last close, which brings the market valuation of the company to $102.71M. CDTX currently trades at a … Cidara Therapeutics Inc. (NASDAQ: CDTX) Could Bring Massive Returns? Read More »

Geode Capital Management LLC trimmed its position in Cidara Therapeutics, Inc. (NASDAQ:CDTX) by 38.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 364,162 shares of the biotechnology companys stock after selling 226,206 shares during the period. Geode Capital Management LLCs holdings in Cidara Therapeutics were worth $735,000 as of its most recent filing []

Cidara Therapeutics (NASDAQ:CDTX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Cidara Therapeutics and Cellectis, []